ArticleClinical case reports2026
When Autoimmunity Meets Malignancy: A Rare Case of Concomitant Systemic Lupus and Multiple Myeloma.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When Autoimmunity Meets Malignancy: A Rare Case of Concomitant Systemic Lupus and Multiple Myeloma.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between systemic lupus erythematosus (SLE) and multiple myeloma (MM) is rare, with fewer than 20 cases reported in the literature, raising questions about the link between chronic immune dysregulation and oncogenesis. We report the case of a 43-year-old Malagasy woman in whom a monoclonal β2-globulin spike, incidentally discovered during the workup of pneumonia, led to the diagnosis of MM. The diagnosis of SLE was straightforward, based on evocative clinical features (photosensitive malar rash, inflammatory arthralgia) and positive autoantibodies (antinuclear antibodies at 1:320, native anti-DNA at 861 IU/mL). Anemia (Hb at 10 g/dL), with a drop of more than 2 g/dL from baseline, and a high erythrocyte sedimentation rate (90 mm) prompted a bone marrow aspiration, which revealed 35% dystrophic clonal plasma cells. A diagnosis of kappa light chain MM was made, without bone lesions. This case highlights three major issues: (1) the diagnosis of MM in a young patient with atypical but fulfilled SLiM-CRAB criteria; (2) a pathophysiological mechanism suggesting chronic B-cell stimulation related to SLE, rather than an iatrogenic effect; (3) the potential role of autologous stem cell transplantation (ASCT) in modulating immune response in both conditions. It underscores the need for diagnostic vigilance, better access to advanced biomarkers, and a multidisciplinary approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.